17554 Holly Well Ave., Tampa, FL 33598
April 29, 2024 According to an article at Biospace.com, GLP-1 agonists are set to become the best-selling drugs in 2024, but the biopharma industry isn’t resting on its collective laurels. Instead, some companies are pushing to improve upon the popular obesity medicines with therapies that promote higher-quality weight loss. Clinical studies have shown that up […]
Higher Quality Weight Loss Drugs Coming in the Future Read More »
March 4, 2024 U.S. Weight Loss Market Now Worth $90 Billion, Obesity Drug Sales Soar March 4, 2024 Marketdata LLC has just published a new analysis of the weight loss market: “The U.S. Weight Loss Market: 2024 Status Report & Forecast”, March 2024, 107 Pages Some findings: The total U.S. weight loss market is estimated
U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs Read More »
Feb. 28, 2024 WW reported its results for Q4 2023 and the full year today. WW reported results in line with analysts’ expectations in Q4 FY2023, with revenue down 8% year on year to $206 million. “2023 was a pivotal year as we began transforming our business for the future. We returned WeightWatchers to year
Weight Watchers Reports Q4 and 2023 Results Read More »
Feb. 20, 2024 Medifast reported full-year and Q4 results on February 20, 2023. 2023 revenues came in at $1.07 billion. The company employed 41,100 active earning Optavia health coaches, who had quarterly earnings of $4,648 (or $18,592 on an annual rate). Management said that: “We are realigning our business to respond to the evolving dynamics
Medifast Reports Q4 and Full Year 2023 Results Read More »
January 20, 2024 Novo Nordisk and Eli Lilly aren’t the only drug companies active in the prescription diet drugs space. Viking Therapeutics has a dual GLP-1/GIP agonist in Phase 2 clinical trials for treating obesity and liver fat reduction for injectable and oral administration. Rhythm Pharmaceuticals has an FDA-approved treatment for the treatment of MC4R-pathway-related
More Obesity Drugs In The Pipeline Read More »
Jan. 11, 2024 The pandemic had significant effects on the way commercial weight loss companies operate, along with the explosive demand for GLP-1 obesity drugs such as Ozempic, Wegovy, and Mounjaro. Marketdata estimates that between Medifast, Weight Watchers, Jenny Craig, and Noom, at least 26,500 weight loss coaches have lost their jobs since 2020. Here’s
Ozempic Boom Is Hurting Weight Loss Coaches Read More »
January 5, 2023 Eli Lilly and Company launched a website, lillydirect.com, to enable people to directly order from the drug maker including its weight-loss medicine Zepbound as well as connect people with obesity and other conditions with telehealth companies. The service, called LillyDirect, comes on the back on extraordinary demand seen over the last year
Eli Lilly Offers Weight Loss Drug Direct to Consumers Read More »
January 4, 2024 The history of weight loss drugs in the U.S. is filled with meds that were taken off the market due to nasty side effects, going back to the phen/fen crisis of 1997. Many more followed (Belviq, Qsymia, Taranabant, Acomplia) . These side effects did not emerge until years after entering the market
Semaglutide Boom – The Beginning of a Decline? New FDA Report Read More »
Dec. 30, 2023 We have started to see TV commercials touting a company called RO, for weight loss. Apparently, this company entered the weight loss market in January 2023, providing GLP-1 weight loss drugs plus coaching, Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the
New Competitor – RO.co (Roman Health Ventures) Read More »
Dec. 14, 2023 Medifast on Wednesday marked its first entry into the medically supported weight loss market through a collaboration with LifeMD Inc., a provider of virtual primary care. This venture brings together Optavia’s personalized, coach-guided approach with medical expertise from board-certified LifeMD clinicians and access to weight loss medications, including GLP-1s. Medifast has committed
Medifast Enters Medical Weight Loss Market Read More »